Mosanna Therapeutics, a Basel, Switzerland-based biotech company, raised an undisclosed amount in a Seed Extension financing round.
New investors Supermoon Capital and HTGF joined founding investor Forty51 Ventures (leader of the overall round) to complete the Seed syndicate.
The company intends to use the funds for manufacturing and regulatory activities in preparation for a multi-study clinical development program.
Founded in 2022 and led by CEO Jonathan Talbot, Mosanna Therapeutics is a biotech company applying a precision medicine approach to develop medicines for high unmet need diseases. The company selects medicines for development using the contract research organisations in the specific specialised field. Its goal is to bring an effective and well tolerated medicinal nasal spray to Metabolic Obstructive Sleep Apnea patients.
Mosanna is on-track to submit an IND by the end of 2023.
FinSMEs
12/04/2023